次世代シーケンシングによりDNAメチル化解析をターゲット

Executive Industry Relevance

Targeted DNA methylation analysis via bisulfite amplicon sequencing (BSAS) addresses the need for high-throughput, quantitative epigenomic profiling in early discovery. It enables precise interrogation of epigenetic regulation in disease-relevant genomic regions, supporting target validation and mechanistic de-risking. The method provides base-specific methylation quantitation that informs hypothesis testing and portfolio triage in preclinical research.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables hypothesis testing of epigenetic mechanisms in target gene promoters or CpG islands.
• Scientific Value: Provides absolute cytosine methylation quantitation with base specificity for functional target validation.
• Operational Value: Supports rapid analysis of up to 96 samples and 10 kb of targeted regions per run.

Screening & Assay Development

• Scientific Value: Generates quantitative methylation data suitable for assay standardization and reproducibility assessment.
• Operational Value: Produces NGS-ready libraries from amplicons for scalable, multiplexed epigenetic screening.
• Operational Value: Facilitates confirmation of regions identified in genome-wide methylation studies through targeted validation.

Translational & Preclinical Research

• Scientific Value: Enables disease-relevant system analysis by comparing methylation patterns across tissues or disease models.
• Scientific Value: Supports translational biomarker alignment through site-specific methylation quantification.
• Operational Value: Provides predictive confidence in epigenetic mechanism de-risking prior to lead identification.

Pipeline & Workflow Integration

BSAS fits within the discovery continuum from target hypothesis testing through lead identification, enabling epigenetic data integration at key decision points.

• Discovery Biology: Supports interrogation of epigenetic regulation in target validation workflows.
• Screening: Delivers quantitative, high-throughput methylation readouts for compound or condition comparison.
• Analytics: Generates variant frequency data at CpG sites for precise methylation level calculation.
• Translational Research: Connects discovery epigenetics to preclinical continuity via tissue-specific methylation profiling.
• Enterprise Reuse: Establishes a reusable capability for targeted epigenetic analysis across multiple projects and model systems.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence in epigenetic mechanism validation and reduction of mechanistic ambiguity.
• Operational Value: Standardization, reproducibility, and scalability of methylation quantification across sample sets.
• Strategic Value: Improved go/no-go decisions through epigenetic de-risking and capital efficiency in target selection.
• Portfolio Impact: Risk-adjusted prioritization based on epigenetic validation of disease-relevant targets.

Implementation Considerations

• Requires expertise in bisulfite conversion, PCR primer design, and NGS library preparation.
• Depends on access to benchtop next-generation sequencing and capillary electrophoresis for library quantification.
• Necessitates cross-team standardization of bioinformatics pipelines for read trimming, mapping, and variant calling.
• Involves adaptation considerations for different DNA sources and genomic regions of interest.
• Limited by the need for prior knowledge of target regions to design specific primers.

Biopharma FAQs